It’s exciting to see new products that make a difference to patients come to market. Multiple treatments improve overall survival (OS) in prostate cancer patients: docetaxel, cabazitaxel, sipuleucel-T, abiraterone acetate and now, radium-223 choloride.
The phase 3 trial results for radium 223 chloride were presented at the 2011 European Multidisciplinary Cancer Congress (ESMO, ECCO, ESTRO) in Stockholm this past weekend.
- Alpharadin will be a new treatment option for Prostate Cancer
- Alpharadin Prostate Cancer data will be “practice changing”
He also took the opportunity to interview Dr Chris Parker, Consultant Clinical Oncologist at The Royal Marsden Hospital, who presented the ALSYMPCA phase 3 trial results, and a video blog post will follow.
Sally Church on Pharma Strategy Blog aggregated all the tweets from the 2011 ESMO ECCO congress in Stockholm. With only a few people tweeting, the twitter stream doesn’t report all the news, but does give a flavor of an excellent cancer meeting with a good balance of science and clinical data.
It’s an exciting time for prostate cancer patients and physicians with multiple new treatment options on the horizon. However, the fast moving and dynamic prostate cancer market is likely to present Pharma/Biotech marketing strategy professionals with opportunities and challenges. Alpharadin is on the fast track to FDA approval in 2012.